The Technical Analyst
Select Language :
Sonnet Biotherapeutics [SONN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Sonnet Biotherapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Sonnet Biotherapeutics is listed at the  Exchange

-4.31% $1.885

America/New_York / 28 mar 2024 @ 13:17


Sonnet Biotherapeutics: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 5.79 mill
EPS: -0.830
P/E: -2.27
Earnings Date: May 07, 2024
SharesOutstanding: 3.07 mill
Avg Daily Volume: 0.108 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.27 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.39x
Company: PE -2.27 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.834
(-2.72%) $-0.0513
Date: 2024-03-28
Expected Trading Range (DAY)

$ 1.734 - 2.04

( +/- 8.01%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-10-27 Rao Raghu Buy 31 250 Warrant to Purchase Common Stock
2023-10-27 Rao Raghu Buy 15 625 Common Stock
2023-10-27 Mohan Pankaj Buy 68 750 Warrant to Purchase Common Stock
2023-10-27 Mohan Pankaj Buy 34 375 Common Stock
2023-08-07 Markey John Sell 0 Common Stock
INSIDER POWER
81.83
Last 88 transactions
Buy: 5 035 351 | Sell: 2 861 714

Forecast: 14:57 - $1.843

Live Trading Signals (every 1 min)

Forecast 1: 13:27 - $1.903
Forecast 2: 14:17 - $1.842
Forecast 3: 14:57 - $1.843
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.885 (-4.31% )
Volume 0.0639 mill
Avg. Vol. 0.108 mill
% of Avg. Vol 58.91 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Sonnet Biotherapeutics Holdings Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Sonnet Biotherapeutics Holdings Inc

RSI

Intraday RSI14 chart for Sonnet Biotherapeutics Holdings Inc

Last 10 Buy & Sell Signals For SONN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Sonnet Biotherapeutics Holdings Inc

SONN

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Last 10 Buy Signals

Date Signal @
SLMMar 28 - 13:37$21.77
PARAMar 28 - 13:36$11.79
GTMar 28 - 13:36$13.78
GEHCMar 28 - 13:3690.62
HTHTMar 28 - 13:36CNY38.37
PEPECOINUSDMar 28 - 13:345.07
BURGERUSDMar 28 - 13:350.883
DKNGMar 28 - 13:34$45.60
ARCCMar 28 - 13:34$20.68
BILIMar 28 - 13:32CNY11.22

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.